Why the study?
Does rivaroxaban prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation?
Population
Patients with nonvalvular atrial fibrillation
Design
Editorial
Authors
Loading...
Highlights regulatory concerns regarding the interpretation of the key study for rivaroxaban in nonvalvular atrial fibrillation.
Does rivaroxaban prevent stroke and systemic embolism in patients with nonvalvular atrial fibrillation?
Highlights regulatory concerns regarding the interpretation of the key study for rivaroxaban in nonvalvular atrial fibrillation.
Fleming et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: